Influenza A virus, Influenza B virus, and Mumps virus antigens

This target group comprises the primary antigenic proteins from Influenza A, Influenza B, and Mumps viruses, which are the central focus of vaccination and antiviral strategies. In Influenza viruses, the surface glycoproteins Hemagglutinin (HA) and Neuraminidase (NA) are essential for the virus to bind to host cells and release new viral particles, respectively [UniProt]. The Mumps virus utilizes the Hemagglutinin-neuraminidase (HN) protein for attachment and the Fusion (F) protein to enter host cells [PubMed]. These antigens are utilized in vaccines, such as the seasonal influenza vaccine and the Mumps component of the MMR vaccine, to elicit a protective immune response characterized by the production of neutralizing antibodies [CDC]. Additionally, specific proteins within this group are targeted by antiviral medications; for instance, neuraminidase inhibitors like oseltamivir prevent the spread of influenza within the host, while cap-dependent endonuclease inhibitors like baloxavir marboxil disrupt viral replication [FDA]. Monitoring the genetic evolution of these antigens, particularly through antigenic drift and shift in influenza, is vital for maintaining the efficacy of therapeutic and prophylactic interventions against seasonal outbreaks [WHO]. Safety considerations for targeting these antigens include potential allergic reactions to vaccine components and rare neurological complications like Guillain-Barré syndrome [NIH].

Other names

Influenza and Mumps antigensFlu A/B and Mumps viral proteinsViral antigens (Influenza and Mumps)

Vaccines induce active immunity by presenting viral antigens to the immune system, leading to the production of neutralizing antibodies and memory B and T cells [CDC]. Neuraminidase inhibitors (e.g., oseltamivir) block the cleavage of sialic acid residues, preventing the release of influenza progeny from infected cells [FDA]. Cap-dependent endonuclease inhibitors (e.g., baloxavir) prevent influenza viral mRNA synthesis by inhibiting the polymerase complex [PubMed]. M2 proton channel blockers (e.g., amantadine) inhibit the uncoating of the influenza A virus within the host cell [StatPearls].